We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Novel Nanogel Drug Delivery System to Undergo Preliminary Clinical Trials

By LabMedica International staff writers
Posted on 21 Apr 2016
Print article
Image: A cutaway illustration of the nanogel drug delivery system. The small particle can carry multiple drug agents to a specific target, such as the site of a tumor (Photo courtesy of Nicolle Rager Fuller, [US] National Science Foundation).
Image: A cutaway illustration of the nanogel drug delivery system. The small particle can carry multiple drug agents to a specific target, such as the site of a tumor (Photo courtesy of Nicolle Rager Fuller, [US] National Science Foundation).
A novel nanogel drug delivery system designed to deliver multiple drugs with different chemical properties is to be tested in a first phase of clinical trials.

In this series of clinical trials, the nanogel system, which was developed at Yale University (New Haven, CT, USA), will be used to transport the drug cocktail IMM-01. The cocktail, which was designed to treat metastatic cancers, comprises two agents, interleukin-2 (IL-2) and an inhibitor of tissue growth factor beta (TGF-beta). IL-2 amplifies the body’s immune system, while the TGF-beta inhibitor dampens the cancer cells’ ability to hide from the immune system.

The biopharmaceutical company Modulate Therapeutics Inc. (Tampa, FL, USA) has secured the rights to bring the drug delivery system to the clinical proof-of-concept stage.

Developer of the nanogel system, Dr. Terek Fahmy, associate professor of biomedical engineering at Yale University, said, "The delivery system is a kind of rational therapy, in that it fuses established biological and clinical findings to the emerging field of nanotechnology. It creates a new solution that could potentially deal a significant blow to cancer and even autoimmune disease in future applications."

Related Links:
Yale University
Modulate Therapeutics

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
HLX
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Real-time PCR System
GentierX3 Series

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: The study showed the blood-based cancer screening test detects 83% of people with colorectal cancer with specificity of 90% (Photo courtesy of Guardant Health)

Blood Test Shows 83% Accuracy for Detecting Colorectal Cancer

Colorectal cancer is the second biggest cause of cancer deaths among adults in the U.S., with forecasts suggesting 53,010 people might die from it in 2024. While fewer older adults are dying from this... Read more

Hematology

view channel
Image: The Gazelle Hb Variant Test (Photo courtesy of Hemex Health)

First Affordable and Rapid Test for Beta Thalassemia Demonstrates 99% Diagnostic Accuracy

Hemoglobin disorders rank as some of the most prevalent monogenic diseases globally. Among various hemoglobin disorders, beta thalassemia, a hereditary blood disorder, affects about 1.5% of the world's... Read more

Microbiology

view channel
Image: The new platform is designed to perform blood-based diagnoses of nontuberculosis mycobacteria (Photo courtesy of 123RF)

New Blood Test Cuts Diagnosis Time for Nontuberculous Mycobacteria Infections from Months to Hours

Breathing in nontuberculous mycobacteria (NTM) is a common experience for many people. These bacteria are present in water systems, soil, and dust all over the world and usually don't cause any problems.... Read more

Industry

view channel
Image: These new assays are being developed for use on the recently introduced DxI 9000 Immunoassay Analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter and Fujirebio Expand Partnership on Neurodegenerative Disease Diagnostics

Beckman Coulter Diagnostics (Brea, CA, USA) and Fujirebio Diagnostics (Tokyo, Japan) have expanded their partnership focused on the development, manufacturing and clinical adoption of neurodegenerative... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.